
16th -17th February 2023



ibc 2023

DIRECTOR

Miguel Martín Hospital General Universitario Gregorio Marañón, Madrid

Innevation in Breast Cancer - iBC 2023

THURSDAY 6 February 2023

16:30-16:45	ntroduction	on

Miguel Martin, Hospital General Universitario Gregorio Marañón, Madrid, Spain

SESSION I: Chair:	GENERAL TOPICS I Ángel Guerrero, Instituto Valenciano de Oncología (IVO), Valencia, Spain
16:45-17:05	In vivo models in breast cancer research: where are we now Karen Blyth, Beatson Institute for Cancer Research, Glasgow, UK
17:05-17:25	Overcoming endocrine resistance in breast cancer Ángel Guerrero, Instituto Valenciano de Oncología (IVO), Valencia, Spain
17:25-17:45	Proton-therapy of Cancer: advantages over standard radiation and current indications Felipe Calvo, Clinica Universitaria de Navarra, Madrid, Spain
17:45-18:15	Discussion
18:15-18:30	Break

SESSION II: Chair:	EARLY BREAST CANCER Luis Costa, Hospital de Santa María, Lisbon, Portugal
18:30-18:50	PARP-1 inhibitors: Any role as neoadjuvant therapy of early BRCA-1/2 associated breast cancer?
	Steven Isakoff, Massachusetts General Hospital Cancer Center, Boston, USA
18:50-19:10	Advances in the adjuvant treatment of HR+/HER2- early breast cancer Miguel Martin, Hospital General Universitario Gregorio Marañón, Madrid, Spain
19:10-19:30	Chemo-immunotherapy for early triple negative breast cancer: which drugs? Priyanka Sharma, University of Kansas Medical Center, Kansas City, USA
19:30-20:00	Discussion

FRIDAY **7** February 2023

SESSION III: Chair:	GENERAL TOPICS II Ander Urruticoechea, Onkologikoa, San Sebastián, Spain
16:00-16:20	ESMO guidelines for breast cancer: how are they made? Curigliano Giuseppe, European Institute of Oncology, Milan, Italy
16:20-16:40	Adherence to oral breast cancer therapies Iván Bustillos, Clínica Portoazul Auna, Barranquilla, Colombia
16:40-17:00	De-escalation of antineoplastic therapies: Principles and considerations Henk van Halteren, Adrz-Admiraal de Ruijter, Medical Cener, Goes, Netherlands
17:00-17:30	Discussion
17:30-17:45	Break
SESSION IV:	TREATMENT OF METASTATIC BREAST CANCER
Chair:	José Enrique Alés, Hospital Ntra. Sra. de Sonsoles, Ávila, Spain
Chair: 17:45-18:05	José Enrique Alés, Hospital Ntra. Sra. de Sonsoles, Ávila, Spain What have we seen from oral SERDs and what could they mean for our patients in future? Aditya Bardia, Massachusetts General Hospital Cancer Center, Boston, USA
	What have we seen from oral SERDs and what could they mean for our patients in future?
17:45-18:05	What have we seen from oral SERDs and what could they mean for our patients in future? Aditya Bardia, Massachusetts General Hospital Cancer Center, Boston, USA Safety management of Antibody-Drug-Conjugates
17:45-18:05 18:05-18:25	What have we seen from oral SERDs and what could they mean for our patients in future? Aditya Bardia, Massachusetts General Hospital Cancer Center, Boston, USA Safety management of Antibody-Drug-Conjugates Maryam Lustberg, Yale University School of Medicine, New Haven, USA Managing brain metastases for HER2+ breast cancer

Innevation in Breast Cancer - / iBC 2022

Organized by



With the scientific endorsement of





Accreditation

Continuinig Education Credits requested to the Spanish National Health System

Symposium secretariat

